Odi Pharma FY26 profit after financial items swings to SEK 1.99 million; net sales rise to SEK 32.92 million

Reuters2026/08/27 16:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Odi Pharma posted FY 2025/2026 net sales of SEK 32.92 million, swinging to profit after financial items of SEK 1.99 million.
EPS turned positive at SEK 0.11, while net sales for the April–June quarter rose to SEK 3.2 million.
Quarterly profit after financial items swung to SEK 153,040; management cited four straight quarters of positive EBITDA.
Working-capital loan balance was repaid in early June, leaving no interest-bearing debt; solidity improved to 45%.
A new commission-based contract via the Swiss subsidiary contributed to net income, with no significant post-period events reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odi Pharma AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202608271200BITN____UKPR__SV_20260827-BIT-3220-0) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Odi Pharma FY26 profit after financial items swings to SEK 1.99 million; net sales rise to SEK 32.92 million

You may also like

Crypto prices